CB 03 01

Drug Profile

CB 03 01

Alternative Names: Breezula; CB-0301; Cortexolone 17alpha-propionate; Winlevi

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cosmo Pharmaceuticals
  • Developer Cassiopea; Cosmo Pharmaceuticals; Intrepid Therapeutics
  • Class Esters; Pregnenediones; Propionates; Small molecules
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acne vulgaris
  • Phase II Alopecia

Most Recent Events

  • 09 May 2017 Phase-II clinical trials in Alopecia in Germany (Topical) (EudraCT2016-003733-23)
  • 01 Oct 2016 Cassiopea initiates a phase II trial for Acne vulgaris (In children) in USA (NCT02720627)
  • 01 May 2016 Intrepid Therapeutics completes a phase II trial in Alopecia in USA (NCT02279823)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top